Lake Street analyst Ben Haynor lowered the firm’s price target on Treace Medical (TMCI) to $7.50 from $12 and keeps a Buy rating on the shares. A roughly 10% sales decline is now implied for Q4 where the firm and consensus had previously modeled growth of about 13%, notes the analyst, who adds that there is “no question updated guidance for FY2025 represented a massive disappointment.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical price target lowered to $5.85 from $6.50 at UBS
- Treace Medical downgraded to Neutral from Buy at BTIG
- Treace Medical downgraded to Underweight from Neutral at JPMorgan
- Treace Medical Concepts Reports Q3 2025 Financial Results
- Treace Medical cuts FY25 revenue view to $211M-$213M from $224M-$230M